Comparison of three quantitation methods for PCNA immunostaining: Applicability and relation to survival in 83 astrocytic neoplasms

The Journal of Pathology

Volumn 171, Issue 3, 1993, Pages 207-214

  Haapasalo, Hannu K ^a   Sallinen, Pauli K ^a   Helen, Pauli T ^a   Rantala, Immo S ^a   Helin, Heikki J ^a   Isola, Jorma J ^b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

astrocytoma; glioblastoma; immunohistochemistry; morphometry; Nervous system tumours; prognosis; proliferating cell nuclear antigen (PCNA); proliferation

Indexed keywords

CYCLINE;

ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER GROWTH; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MORPHOMETRICS; PRIORITY JOURNAL; PROGNOSIS;

ASTROCYTOMA; AUTOANTIGENS; BRAIN NEOPLASMS; CELL COUNT; COMPARATIVE STUDY; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MITOTIC INDEX; NUCLEAR PROTEINS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0027366713     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1711710309     Document Type: Article

References (21)

1. An auxiliary protein for DNA polymerase delta from fetal calf thymus
2. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle
3. Cell cycle‐dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase
4. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA): structural conservation and the detection of a nucleolar form
5. PCNA immunohistochemistry using MoAb 19A2 and a new antigen retrieval has prognostic impact in archival paraffin‐embedded node‐negative breast cancer
6. Proliferating cell nuclear antigen expression in central nervous system neoplasms
7. Proliferating cell nuclear antigen (PCNA) immunostaining as an alternative to bromodeoxyuridine (BrdU) immunostaining for brain tumours in paraffin embedded sections
8. Proliferating cell nuclear antigen and Ki‐67 immunohistochemistry in brain tumours: a comparative study
9. Forecasting the prognosis of a patient with a tumour
10. Prognostic implications of p53 protein, epidermal growth factor receptor and Ki‐67 labelling in brain tumours
11. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling
12. Volume corrected mitotic index—the standard of mitotic activity in neoplasms
13. Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections
14. Silver enhancement of polysensitivity for immunoperoxidase staining
15. Mitosis counting—a need for reappraisal
16. Prognosis of ovarian carcinomas: prediction by histoquantitative methods
17. Independent clinical, histological and quantitative prognostic factors in transitional‐cell bladder tumours, with special reference to mitotic frequency
18. Volume corrected mitotic index (M/V index) in pancreatic cancer: relation to histological grade, clinical stage and prognosis
19. Mitotic indexes as prognostic predictors in female breast cancer